portal vein thrombosis anticoagulation | Update on Management of Porta

Keyword	CPC	PCC	Volume	Score	Length of keyword
portal vein thrombosis anticoagulation	1.86	0.2	3269	37	38
portal	0.6	0.8	1810	50	6
vein	1.82	0.7	5635	72	4
thrombosis	0.07	0.5	7531	77	10
anticoagulation	0.07	0.8	6919	56	15

Keyword	CPC	PCC	Volume	Score
portal vein thrombosis anticoagulation	1.06	0.1	1658	90
portal vein thrombosis anticoagulation doac	0.23	0.2	3665	73
portal vein thrombosis anticoagulation choice	1.53	0.5	4753	59
portal vein thrombosis and anticoagulation	0.02	1	1882	80
portal vein thrombosis management	1.52	0.8	223	25
portal vein thrombosis patient information	0.94	0.5	5575	27
portal vein thrombosis medication	0.24	1	9949	99
portal vein thrombosis us	1.27	0.8	106	74
portal vein thrombosis guidelines	2	0.5	5576	58
thrombosis in portal vein	0.17	0.1	7411	33
portal vein thrombosis nhs	0.78	1	3196	98
portal vein thrombosis treatment guidelines	0.15	0.2	3809	22
portal vein thrombosis treatment	0.42	0.1	9642	78
pulmonary vein thrombosis anticoagulation	1.29	0.6	2727	99
portal vein thrombosis review	0.86	0.5	2778	56
how to treat portal vein thrombosis	1.99	0.9	8514	38
acute portal vein thrombosis	0.95	0.7	2748	77
portal vein thrombosis investigation	0.1	0.1	2792	61
pvt portal vein thrombosis	0.97	0.3	5488	7

Search Results related to portal vein thrombosis anticoagulation on Search Engine

Update on Management of Portal Vein Thrombosis and the Role …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609842/

WEBJun 6, 2019 · • The role of anticoagulation in patients with portal vein thrombosis and cavernous transformation is very unclear: PVT in cirrhotics • No generalized recommendation • Anticoagulation to be considered on case-by-case basis • Consider anticoagulation at therapeutic dose for atleast 6 months (B1)

DA: 80 PA: 71 MOZ Rank: 47

AGA Clinical Practice Guideline on the Management of …
gastrojournal.org

https://www.gastrojournal.org/article/S0016-5085(21)03382-5/fulltext

WEBSep 24, 2021 · Although these patients are at risk for thrombosis—including deep vein thrombosis, pulmonary embolism, splanchnic vein thrombosis, or stroke—there has been some trepidation on the part of clinicians to treat them with conventional anticoagulants, such as vitamin K antagonists (VKAs).

DA: 36 PA: 77 MOZ Rank: 37

Acute portal vein thrombosis in adults: Clinical ... - UpToDate
uptodate.com

https://www.uptodate.com/contents/acute-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management

WEBAug 29, 2022 · Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management; Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis; Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects; Epidemiology and pathogenesis of portal …

DA: 68 PA: 60 MOZ Rank: 82

Portal Vein Thrombosis - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK534157/

WEBNov 23, 2022 · In acute non-cirrhotic portal vein thrombosis with an early diagnosis with improved diagnostic techniques and use of early anticoagulation, the 5-year survival rate has now improved to 85%. The outcome of PVT is good, and mortality primarily is due to an underlying cause or as consequences of portal hypertension.

DA: 48 PA: 48 MOZ Rank: 46

Consensus for management of portal vein thrombosis in liver …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252415/

WEBMar 7, 2021 · The type, dosage, and duration of anticoagulants may influence the treatment outcomes of PVT in liver cirrhosis. Therefore, an anticoagulation strategy for cirrhotic PVT should be further optimized. Hemorrhage is one of the most common adverse events of anticoagulants.

DA: 54 PA: 66 MOZ Rank: 64

ACG Clinical Guideline: Disorders of the Hepatic and Mesente ... - LWW
lww.com

https://journals.lww.com/ajg/fulltext/2020/01000/acg_clinical_guideline__disorders_of_the_hepatic.9.aspx

WEBFree. Metrics. Abstract. Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.

DA: 9 PA: 22 MOZ Rank: 56

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis
nejm.org

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200104

WEBNov 22, 2022 · In patients with noncirrhotic chronic portal vein thrombosis (PVT), the benefit of long-term anticoagulation is unknown. We assessed the effects of rivaroxaban on the risk of venous...

DA: 5 PA: 25 MOZ Rank: 37

Treatment of portal vein thrombosis: an updated narrative review
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33832217/

WEBAnticoagulants. Portal vein thrombosis (PVT) is the most frequent among the splanchnic vein thrombosis, accounting for 90% of cases. More than half of PVT are provoked by liver cirrhosis, solid cancer or myeloproliferative neoplasms. The remaining cases are non-malignant non-cirrhotic PVT and include either unprovo …

DA: 67 PA: 78 MOZ Rank: 64

Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis …
ashpublications.org

https://ashpublications.org/blood/article/138/Supplement%201/671/479493/Treatment-of-Portal-Mesenteric-and-Splenic-Vein

WEBNov 5, 2021 · Abstract. Introduction: Anticoagulation plays a crucial role in the treatment of splanchnic vein thrombosis (SVT), including thrombosis of the portal (PVT), mesenteric (MVT) and splenic (SpVT) veins. Rivaroxaban is a potential alternative to heparins and vitamin K antagonists (VKA) in these patients, but data to support its use are scant.

DA: 87 PA: 4 MOZ Rank: 13

Portal Interventions in the Setting of Venous Thrombosis or …
rsna.org

https://pubs.rsna.org/doi/10.1148/rg.220020

WEBOct 3, 2022 · Portal vein thrombosis most commonly occurs as a complication of liver cirrhosis and can result in worsening symptoms of portal hypertension, which often can be challenging to treat with conventional decompression therapies.

DA: 90 PA: 7 MOZ Rank: 12